A Study of Azidothymidine (AZT) in the Treatment of HIV Infection in Patients Receiving a Bone Marrow Transplant
This study has been completed.
Sponsor:
Glaxo Wellcome
Information provided by:
NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:
NCT00002284
First received: November 2, 1999
Last updated: June 23, 2005
Last verified: February 1995
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
![](https://webarchive.library.unt.edu/web/20130228093354im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
To determine whether zidovudine (AZT) in conjunction with bone marrow transplantation prevents the reinfection of donor hematopoietic/lymphoid cells in patients with positive HTLV III antibody and large cell/diffuse histiocytic lymphoma. Patients who are candidates will be evaluated for HTLV III activity and drug levels.
Condition | Intervention |
---|---|
Lymphoma, Non-Hodgkin HIV Infections |
Drug: Zidovudine |
Study Type: | Interventional |
Study Design: | Primary Purpose: Treatment |
Official Title: | A Pilot Study To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients Receiving a Bone Marrow Transplant |
Resource links provided by NLM:
Genetics Home Reference related topics:
complement factor I deficiency
Drug Information available for:
Zidovudine
U.S. FDA Resources
Further study details as provided by NIH AIDS Clinical Trials Information Service:
![](https://webarchive.library.unt.edu/web/20130228093354im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Ages Eligible for Study: | 12 Years to 50 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Criteria
Exclusion Criteria
Co-existing Condition:
Patients with current life-threatening infection at time of transplant that would preclude a transplant are excluded.
Concurrent Medication:
Excluded:
- Other anti-retroviral agents.
Patients with current life-threatening infection at time of transplant that would preclude a transplant are excluded.
Patients must be:
- HTLV III antibody positive by ELISA or Western blot or HTLV III viremia.
- At high mortal risk with a diagnosis of AIDS or AIDS Related Complex (ARC).
- Also patient must fall into one of the following categories:
- Have an HIV seronegative identical twin to serve as a bone marrow donor.
- Have documentation of large cell/diffuse histiocytic lymphoma/DPDL.
- Be a good risk candidate for bone marrow transplant.
![](https://webarchive.library.unt.edu/web/20130228093354im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
![](https://webarchive.library.unt.edu/web/20130228093354im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
No publications provided
ClinicalTrials.gov Identifier: | NCT00002284 History of Changes |
Other Study ID Numbers: | 014A, 006 |
Study First Received: | November 2, 1999 |
Last Updated: | June 23, 2005 |
Health Authority: | United States: Food and Drug Administration |
Keywords provided by NIH AIDS Clinical Trials Information Service:
Lymphoma, Large-Cell Acquired Immunodeficiency Syndrome AIDS-Related Complex Zidovudine Bone Marrow Transplantation |
Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome HIV Infections Lymphoma Lymphoma, Non-Hodgkin Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Slow Virus Diseases Immunologic Deficiency Syndromes Immune System Diseases Neoplasms by Histologic Type Neoplasms |
Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Zidovudine Antimetabolites Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Therapeutic Uses Anti-HIV Agents |
ClinicalTrials.gov processed this record on February 26, 2013